Role of contrast enhanced mammography with Iomeprol 400 mgI/ml (Iomeron, Bracco), in the identification of breast cancer: I3-MaC Study

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513251-32-00

Acronym

I3-MaC Study

Enrollment

173

Registered

2024-07-09

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Brief summary

Main Parameters evaluations • Dose of contrast administered (mL) • Contrast flow rate (mL/s) • Creatinine • BUN • VFG • Serum Albumin • Na • K • eGFR

Detailed description

• Pre-CEM mammography and breast ultrasound • Follow-up mammography and breast ultrasound, 6 and 12 months after CEM

Interventions

DRUGIOMEPROL

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Main Parameters evaluations • Dose of contrast administered (mL) • Contrast flow rate (mL/s) • Creatinine • BUN • VFG • Serum Albumin • Na • K • eGFR	—

Secondary

Measure	Time frame
• Pre-CEM mammography and breast ultrasound • Follow-up mammography and breast ultrasound, 6 and 12 months after CEM	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026